Obesity and Mortality Risk in Critically Ill Children

Patrick A Ross1, Christopher J L Newth2, Dennis Leung2

  • 1Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California paross@chla.usc.edu.

Pediatrics
|February 25, 2016
PubMed

Insights

Childhood obesity is linked to higher pediatric intensive care unit (PICU) mortality. Accurate classification requires height and weight data to avoid misinterpreting mild obesity as protective.

Area of Science:

  • Pediatric critical care medicine
  • Public health and epidemiology
  • Obesity research

Background:

  • Childhood obesity is a significant public health concern with potential implications for pediatric intensive care unit (PICU) outcomes.
  • Previous studies suggest a possible association between obesity and mortality in critically ill children.

Purpose of the Study:

  • To investigate the association between obesity and PICU mortality, adjusting for illness severity.
  • To compare the impact of height- and weight-based obesity classifications on mortality distribution.

Main Methods:

  • Retrospective analysis of prospectively collected data from a large multicenter PICU database.
  • Calculation of BMI z-scores using CDC and WHO growth curves.
  • Multivariable logistic regression to assess the association between obesity and mortality, controlling for covariates.

Main Results:

  • Over 127,000 patients were analyzed, with a 2.48% mortality rate.
  • Overweight classification was independently associated with increased PICU mortality after adjusting for illness severity and comorbidities.
  • Mortality exhibited a U-shaped distribution when classified by weight-for-age or weight-for-height/BMI.

Conclusions:

  • Risk-adjusted PICU mortality increases with higher weight-for-height/BMI (overweight and obese ranges).
  • Height data are crucial for accurate body habitus classification in critically ill children.
  • Excluding height can lead to misinterpretations of mild obesity as having a protective effect.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
335
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
368
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
279
Anorexia Nervosa01:28

Anorexia Nervosa

Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
1.8K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693